Cart
sales@molnova.com
BMS-741672
CAS No. 1004757-96-3
BMS-741672( BMS741672 )
Catalog No. M10035 CAS No. 1004757-96-3
BMS-741672 is a potent, selective CCR2 antagonist for the treatment of neuropathic pain.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 1863 | Get Quote |
|
| 50MG | 3762 | Get Quote |
|
| 100MG | 5220 | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameBMS-741672
-
NoteResearch use only, not for human use.
-
Brief DescriptionBMS-741672 is a potent, selective CCR2 antagonist for the treatment of neuropathic pain.
-
DescriptionBMS-741672 is a potent, selective CCR2 antagonist for the treatment of neuropathic pain.Diabetes Phase 2 Clinical.
-
In Vitro——
-
In Vivo——
-
SynonymsBMS741672
-
PathwayGPCR/G Protein
-
TargetChemokine Receptor
-
RecptorChemokine Receptor
-
Research AreaMetabolic Disease
-
IndicationDiabetes
Chemical Information
-
CAS Number1004757-96-3
-
Formula Weight506.574
-
Molecular FormulaC25H33F3N6O2
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESCC(N[C@H]1[C@@H](N2C([C@@H](NC3=C4C=C(C(F)(F)F)C=CC4=NC=N3)CC2)=O)CC[C@@H](N(C(C)C)C)C1)=O
-
Chemical NameN-((lR,2S,5R)-5-(isopropyl(methyl)amino)-2-((S)-2-oxo-3-(6- (trifluoromethyl)quinazolin-4-ylamino)pyrrolidin-l-yl)cyclohexyl)acetamide
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Joerg Deerberg, et al. Org. Process Res. Dev., 2016, 20 (11), pp 1949-1966.
molnova catalog
related products
-
ML 604086
ML 604086 (ML604086) is a potent, selective CCR8 inhibitor that inhibits CCL1 mediated chemotaxis and increases in intracellular Ca2+ concentrations with IC50 of 1.3?uM and 1.0?uM respectively in cellular assays.
-
POL3026
A highly potent, selective beta-hairpin mimetic CXCR4 inhibitor with IC50 of 1.2 nM in Ca2+ flux assay.
-
Ladarixin sodium
A novel allosteric, noncompetitive dual CXCR1/2 inhibitor that inhibits human polymorphonuclear leukocyte (PMN) migration to CXCL8 in vitro with IC50 of 0.7 nM.
